Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Axokine Obesity Trial Setback Weighs Down Regeneron On Wall Street

  • News

Executive Summary

Regeneron will explore ways to fine-tune its investigational obesity agent Axokine to increase the percentage of patients that do not develop antibodies to the protein, CEO Leonard Schleifer, MD/PhD, said

You may also be interested in...



Sanofi Chews The Fat: Rimonabant Anti-Obesity NDA To Be Filed By 2005

Sanofi-Synthelabo expects to file an NDA for rimonabant in obesity by the first quarter of 2005, Exec VP-Scientific Affairs Gerard Le Fur told analysts during a business review in London Sept. 2

Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal

Aventis and Regeneron are pursuing a colorectal indication for Regeneron's vascular endothelial growth factor trap after seeing positive results from Genentech's Phase III VEGF inhibitor Avastin

Sanofi Chews The Fat: Rimonabant Anti-Obesity NDA To Be Filed By 2005

Sanofi-Synthelabo expects to file an NDA for rimonabant in obesity by the first quarter of 2005, Exec VP-Scientific Affairs Gerard Le Fur told analysts during a business review in London Sept. 2

Table

View full table

Tags:
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier

US FDA’s PDUFA VIII Ideas Could Include Creating Regulatory Science Research Program

Medicare Part B Inflation Rebate List Doubles For Third Quarter, Adds Several Amgen Drugs

See All
UsernamePublicRestriction

Register

PS041550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By